A study on adaptive treatment decision-making guided by multi-omics typing of small cell lung cancer in China.

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2400094724

Enrollment

Unknown

Registered

2024-12-26

Start date

2025-01-01

Completion date

Unknown

Last updated

2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Small cell lung cancer

Interventions

Observation group:N/A

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Initial treatment SCLC: =18 years old. Histologically confirmed SCLC. VALG staging ES-SCLC or LS-SCLC without prior treatment. ECOG 0-2. At least one measurable lesion. Recurrent SCLC: =18 years old. Histologically confirmed SCLC. SCLC with progression after treatment with at least one regimen. ECOG 0-2. At least one measurable lesion.

Exclusion criteria

Exclusion criteria: Mixed small cell lung cancer. Transformed small cell lung cancer. History of other malignancies within the past 5 years.

Design outcomes

Primary

Measure	Time frame
whole exome sequencing;RNA-seq;Proteomic sequencing;scRNA-seq;Spatial transcriptome sequencing;ctDNA detection;	—

Countries

China

Contacts

Public ContactYing Cheng

Jilin Cancer Hospital

chengying@csco.org.cn+86 139 4301 2851

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026